Loading...
Pyoderma gangrenosum (PG), a rare inflammatory ulceration of the skin, has an unknown pathogenesis, but a variety of inflammatory mediators seem to drive the observed neutrophilic infiltrate. Increased interleukin (IL)-1β levels have been demonstrated in patients with PG as part of an autoinflammatory syndrome. The biologic canakinumab targets IL-1β and is approved for use in cryopyrin-associated autoinflammatory syndromes. It has demonstrated effectiveness in single cases of PG-associated syndromic autoinflammatory disorders.
These investigators performed an open-label study of five patients with refractory nonsyndromic PG not associated with systemic disease. All patients were resistant to systemic corticosteroids and at least one addition…